PREPARATION AND CHARACTERIZATION OF PEG-ALBUMIN-ANASTRAZOLE (PAA) NANOPARTICLES INTENDED TO TREAT BREAST CANCER

Author(s): Ramchander Tadakapally*, Jithan Aukunuru and Mohammad Habbibudin

Abstract: The aim of present research is to prepare serum stable long- circulating polymeric nanoparticles for Anastrazole by NAB (Nanoparticle albumin bound) technology for breast cancer treatment. Nanoparticles were prepared by desolvation technique. After preparation, nanoparticles were characterized for particle size, scanning electron microscope (SEM), zeta potential, drug entrapment efficiency (EE), Fourier transform infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC). Solubility and in vitro release of the drug from nanoparticles are determined. With optimized formulation In-vivo drug release issue, Kupffer cell uptake and tissue uptake was determined, cell viable assay was performed. In vitro studies were performed in phosphate buffer saline pH 7.4 at 37˚ ± 0.5˚C for 30 days. Sustained drug release from nanoparticles was observed for 18 days. Cell viability assay was determined with optimized formulation. Solubility of the drug is increased by pegylated nanoparticles. The entrapment efficiency was about 92.0 %, the mean particle size of obtained nanoparticles was 119 - 319 nm, and it was spherical with a smooth surface. The zeta potential is found to be -64 mV, and the nanoparticles are found to be stable. FT - IR studies conducted drug - excipient interaction studies, demonstrating that the drug was not changed during the fabrication process. The DSC results also showed no significant shift in the endothermic peaks confirming the drug’s stability in the formulations. Polymeric peaks revealed that, the drug is in amorphous state in the formulations. The pegylated anastrazole polymeric nanoparticles released the drug with a small initial burst followed by a slower and controlled release with improved of 5- fold than pure drug.

PAGES: 727-737  |  39 VIEWS  116 DOWNLOADS